Fgfr3 enhancer deletion markedly improves all skeletal features in a mouse model of achondroplasia
Journal of Clinical Investigation · 2025
DOI: 10.1172/jci184929 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von Marco Angelozzi und 6 weiteren Autor:innen. Hauptthemen laut MEDLINE: Achondroplasia, Receptor, Fibroblast Growth Factor, Type 3, Enhancer Elements, Genetic, Sequence Deletion. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAMS NIH HHS, Caen University Hospital Reference Center for Rare diseases of Calcium and Phosphate Metabolism, National Institute of Arthritis and Musculoskeletal and Skin Diseases.
Abstract (Originalsprache)
Achondroplasia, the most prevalent short-stature disorder, is caused by missense variants overactivating the fibroblast growth factor receptor 3 (FGFR3). As current surgical and pharmaceutical treatments only partially improve some disease features, we sought to explore a genetic approach. We show that an enhancer located 29 kb upstream of mouse Fgfr3 ( –29E ) is sufficient to confer a transgenic mouse reporter with a domain of expression in cartilage matching that of Fgfr3 . Its CRISPR/Cas9-mediated deletion in otherwise WT mice reduced Fgfr3 expression in this domain by half without causing adverse phenotypes. Importantly, its deletion in mice harboring the ortholog of the most common human achondroplasia variant largely normalized long bone and vertebral body growth, markedly reduced spinal canal and foramen magnum stenosis, and improved craniofacial defects. Consequently, mouse achondroplasia is no longer lethal, and adults are overall healthy. These findings, together with high conservation of –29E in humans, open a path to develop genetic therapies for people with achondroplasia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Förderung
- NIAMS NIH HHS
- Caen University Hospital Reference Center for Rare diseases of Calcium and Phosphate Metabolism
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
Zitieren
APA
Angelozzi, M., Molin, A., Karvande, A., Fernández-Iglesias, Á., Whipple, S., Bloh, A. M., & Lefebvre, V. (2025). Fgfr3 enhancer deletion markedly improves all skeletal features in a mouse model of achondroplasia. Journal of Clinical Investigation. https://doi.org/10.1172/jci184929
Vancouver
Angelozzi M, Molin A, Karvande A, Fernández-Iglesias Á, Whipple S, Bloh AM, et al. Fgfr3 enhancer deletion markedly improves all skeletal features in a mouse model of achondroplasia. Journal of Clinical Investigation. 2025. doi:10.1172/jci184929
BibTeX
@article{Angelozzi2025,
author = {Angelozzi, Marco and Molin, Arnaud and Karvande, Anirudha and Fernández-Iglesias, Ángela and Whipple, Samantha and Bloh, Andrew M and Lefebvre, Véronique},
title = {Fgfr3 enhancer deletion markedly improves all skeletal features in a mouse model of achondroplasia},
journal = {Journal of Clinical Investigation},
year = {2025},
doi = {10.1172/jci184929}
}
EUVIMED